Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review.
Paolo StratiTara GregoryNavneet S MajhailNitin JainPublished in: JCO oncology practice (2023)
Chimeric antigen receptor T-cell (CAR-T) therapy has become an established therapeutic approach for the treatment of hematologic malignancies. The field continues to evolve rapidly and newer-generation constructs are being designed to enhance proliferative capacity, and achieve long-term persistence and greater efficacy with an overall lower incidence of toxicity. Initial clinical application of CAR-T therapies has focused on relapsed and/or refractory hematologic malignancies, and Food and Drug Administration-approved CAR-T products targeting CD19 are available for B-cell acute lymphoblastic leukemia and low- and high-grade B-cell non-Hodgkin lymphoma, and targeting B-cell maturation antigen are available for multiple myeloma. Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome have been recognized as class specific toxicities associated with these novel therapies. In this review, we focus on the clinical application of CAR-T therapies in adult patients with hematologic malignancies, including access issues, outpatient administration, and appropriate timing for referring a patient to a CAR-T treatment center.
Keyphrases
- acute lymphoblastic leukemia
- multiple myeloma
- high grade
- drug administration
- case report
- cancer therapy
- oxidative stress
- risk factors
- combination therapy
- diffuse large b cell lymphoma
- hodgkin lymphoma
- low grade
- drug delivery
- dendritic cells
- allogeneic hematopoietic stem cell transplantation
- climate change
- smoking cessation